News
Crystal Bio Appoints Dr. Ye Gu as Co-founder, CTO, and Head of USA BD
14 May 2024
en
Suzhou, China - Recently, Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services (CFS) announced that it is honored to have received high recognition from their client, Brise Pharma, for the exceptional high quality technical services for a drug product development project. The formulation team from Brise Pharma presented a commemorative “Best Partner” trophy to CFS in recognition of its outstanding performance throughout the collaboration.
This honor not only affirms the hard work and excellence of the CFS R&D team but also reflects the close and successful partnership between the two companies.
Brise Pharma and CFS established deep collaboration throughout key stages of drug product development. Leveraging extensive formulation development experience, CFS consistently followed a customer-driven approach, upholding sound scientific principles and rigorous quality standards. The CFS team proactively moved the project forward and implemented highly efficient project management to ensure smooth progress and the timely delivery of excellent results.
Ms. Ting Liu, the representative from the Brise Pharma formulation team said, “We sincerely thank the Crystal Formulation Services team for their support! From project initiation to final delivery, our collaboration has been very close. The CFS technical team paid great attention to data details during research and development, efficiently identified the optimal formulation–process combination, and successfully achieved the project goals, laying a solid foundation for the next stages of our development. This achievement is inseparable from the diligent work and strong support of the CFS project team. We look forward to continuing our in-depth cooperation in formulation development and GMP manufacturing.”
Dr. Alex Chen, CEO of Crystal Group, stated: “We are honored to receive the Best Partner award from our innovative drug client Brise Pharma. The project showcases how CFS enabled a new drug to achieve first-attempt clinical success through advanced formulation technology. With tightly coordinated efforts, from issue identification and formulation development to manufacturing and clinical evaluation, we precisely controlled in-vivo release and absorption to enhance the drug’s clinical value.”
Dr. Chen further added, “In recent years, we have taken on many projects that faced delays or failure due to selecting the wrong formulation partner early on. We welcome global clients to bring us their challenging and high-difficulty molecules, and we remain committed to reducing clinical setbacks caused by non-customized formulation strategies. Applying formulation science early is vital for risk control, and choosing the right strategy from the start is essential. We believe every new drug molecule deserves a First-Time-Right crystal form and formulation. This is the mission of Crystal Pharmatech.”
Dr. Decheng Ma, CEO of CFS stated, “We are greatly honored to receive Brise Pharma’s recognition and the ‘Best Partner’ title. This acknowledgment highlights CFS’s professional capabilities in the drug product CDMO field and motivates us to continuously enhance our service quality. CFS will remain customer-centric, grounded in scientific rigor and a high-quality service system. We will continue to deepen our expertise in formulation R&D and manufacturing, constantly optimize our service capabilities, and support innovative pharmaceutical companies in achieving their development goals.”
Brise Pharma stands as a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatment solutions for severe pain conditions, especially for addressing issues such as migraine, inflammatory pain, and neuropathic pain.
Brise Pharma was originally formed by a group of veterans with an average of over 15 years of extensive experience in drug R&D with a global perspective, ranging from preclinical study, clinical development, to financing, investment, and company operations.
Crystal Formulation Services (CFS), a wholly owned subsidiary of Crystal Pharmatech Co., Ltd., was founded in July 2021 in Suzhou, Jiangsu, China. CFS provides oral formulation development and manufacturing services for innovative drug products around the world.
As a formulation CDMO, our team has rich formulation development experience, developing over 100 NCEs (new chemical entities). Our management team has a track record for the successful commercialization of 15 drug products. Our basis is sound science and engineering, focusing on the interplay of composition design and process development. We believe in the MMM formulation development strategy, which empowers Molecule, Material, and Medicine. Based on scientific excellence, we provide our clients the best formulation for clinical development, which is bioavailable, scalable, robust, and stable. We dive deeply into oral formulation science and strive to become a first-class CDMO in this area.
Subscribe to be the first to get the updates!
